Immune-Onc Raises $73 Million for Novel Immunosuppressive Checkpoints

Immune-Onc Therapeutics of Palo Alto, CA raised $73 million in a Series B1 and B2 financing led by Oceanpine Capital, a Beijing-based venture firm. Immune-Onc is a clinical-stage cancer immunotherapy company that targets immunosuppressive myeloid checkpoints. To overcome cancer immune resistance, the company's R&D focuses on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) of myeloid checkpoints. Immune-Onc aims to test its candidate in blood cancers and solid tumors. More details.... Share this with colleagues: // //